Cargando…
The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells
BACKGROUND: Prostate cancer (PCa) is one of the most frequently diagnosed tumors in men. In general, therapies for localized PCa are curative. However, treatment of advanced PCa is considered palliative since development of therapy resistance occurs rapidly. It has been shown that tumor‐initiating c...
Autores principales: | Gruber, Martina, Handle, Florian, Culig, Zoran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003856/ https://www.ncbi.nlm.nih.gov/pubmed/31834633 http://dx.doi.org/10.1002/pros.23940 |
Ejemplares similares
-
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
por: Gruber, Martina, et al.
Publicado: (2020) -
Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
por: Vakhrusheva, Olesya, et al.
Publicado: (2022) -
STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel
por: Rocha, Sandra M., et al.
Publicado: (2023) -
Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles
por: Gao, Jie, et al.
Publicado: (2019) -
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells
por: Puhr, Martin, et al.
Publicado: (2014)